BIGNOTTI, Eliana
 Distribuzione geografica
Continente #
NA - Nord America 4.023
EU - Europa 1.734
AS - Asia 1.726
SA - Sud America 255
AF - Africa 38
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 7.786
Nazione #
US - Stati Uniti d'America 3.939
CN - Cina 600
SG - Singapore 545
PL - Polonia 385
IT - Italia 271
DE - Germania 237
BR - Brasile 218
UA - Ucraina 215
HK - Hong Kong 187
FI - Finlandia 148
VN - Vietnam 129
GB - Regno Unito 106
FR - Francia 84
TR - Turchia 55
IN - India 52
CA - Canada 51
RU - Federazione Russa 47
EE - Estonia 46
IE - Irlanda 45
BD - Bangladesh 29
ES - Italia 27
SE - Svezia 25
ID - Indonesia 23
IQ - Iraq 20
NL - Olanda 20
MX - Messico 19
ZA - Sudafrica 17
AR - Argentina 15
BE - Belgio 14
CZ - Repubblica Ceca 14
AT - Austria 11
JP - Giappone 11
LT - Lituania 11
BG - Bulgaria 7
EC - Ecuador 7
PK - Pakistan 7
KG - Kirghizistan 6
SA - Arabia Saudita 6
TW - Taiwan 6
JO - Giordania 5
KR - Corea 5
AE - Emirati Arabi Uniti 4
AU - Australia 4
LK - Sri Lanka 4
MY - Malesia 4
OM - Oman 4
TN - Tunisia 4
UZ - Uzbekistan 4
AZ - Azerbaigian 3
CL - Cile 3
CR - Costa Rica 3
EU - Europa 3
IL - Israele 3
LV - Lettonia 3
MA - Marocco 3
NG - Nigeria 3
PT - Portogallo 3
PY - Paraguay 3
RO - Romania 3
UY - Uruguay 3
VE - Venezuela 3
AL - Albania 2
BB - Barbados 2
BH - Bahrain 2
CO - Colombia 2
ET - Etiopia 2
HN - Honduras 2
HU - Ungheria 2
JM - Giamaica 2
KE - Kenya 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MU - Mauritius 2
NP - Nepal 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AQ - Antartide 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BW - Botswana 1
BY - Bielorussia 1
CI - Costa d'Avorio 1
DZ - Algeria 1
EG - Egitto 1
GT - Guatemala 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LY - Libia 1
MT - Malta 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
RS - Serbia 1
SV - El Salvador 1
TH - Thailandia 1
TJ - Tagikistan 1
TO - Tonga 1
Totale 7.786
Città #
Fairfield 408
Ashburn 400
Warsaw 383
Singapore 314
Woodbridge 297
Houston 211
Seattle 201
Chandler 194
San Jose 193
Hong Kong 169
New York 160
Jacksonville 147
Cambridge 136
Wilmington 132
Ann Arbor 121
Beijing 116
Dearborn 109
The Dalles 109
Helsinki 108
Los Angeles 87
Princeton 74
Munich 61
Brescia 57
Nanjing 47
Tallinn 46
Dublin 45
Lauterbourg 42
Istanbul 40
Shanghai 38
Des Moines 35
Dallas 34
Milan 33
Council Bluffs 31
Hangzhou 30
Ho Chi Minh City 30
San Francisco 28
Chicago 27
São Paulo 27
Toronto 27
London 26
Buffalo 25
Dong Ket 24
Jinan 24
Hanoi 23
Moscow 22
Santa Clara 22
Nanchang 21
Shenyang 21
Orem 20
Kunming 19
Turku 18
Rome 16
San Diego 15
Tianjin 15
Hebei 14
Montreal 14
Brussels 13
Central 13
Chennai 13
Redondo Beach 13
Changsha 12
Denver 12
Jakarta 12
Brooklyn 11
Johannesburg 11
Guangzhou 10
Monmouth Junction 10
Phoenix 10
Poplar 10
Tokyo 10
Belo Horizonte 9
Mexico City 9
Paris 9
Stockholm 9
Zhengzhou 9
Badalona 8
Boston 8
Jiaxing 8
Mumbai 8
Nuremberg 8
Vienna 8
Ankara 7
Atlanta 7
Brno 7
Charlotte 7
Hefei 7
Leawood 7
Manchester 7
Ningbo 7
Rio de Janeiro 7
Amsterdam 6
Bishkek 6
Frankfurt am Main 6
Haiphong 6
Kilburn 6
Kyiv 6
New Delhi 6
Olomouc 6
Verona 6
Baghdad 5
Totale 5.461
Nome #
Identification of stably expressed reference small non-coding RNAs for microRNA quantification in high-grade serous ovarian carcinoma tissues 355
Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):2916-21. doi: 10.1073/pnas.1222577110. Epub 2013 Jan 28. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Zhao S1, Choi M, Overton JD, Bellone S, Roque DM, Cocco E, Guzzo F, English DP, Varughese J, Gasparrini S, Bortolomai I, Buza N, Hui P, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Carrara L, Pecorelli S, Silasi DA, Ratner E, Azodi M, Schwartz PE, Rutherford TJ, Stiegler AL, Mane S, Boggon TJ, Schlessinger J, Lifton RP, Santin AD 351
Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. 328
A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment 231
Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. 219
Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts 209
Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone 207
Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer 206
Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy. 200
Secretoglobin expression in ovarian carcinoma: lipophilin B gene upregulation as an independent marker of better prognosis. 198
Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma 197
Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes 193
Gene expression profiling to improve prognostic characterization of olfactory neuroblastoma and to define new targetable pathways 190
Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. 187
Identification of optimal reference genes for gene expression normalization in a wide cohort of endometrioid endometrial carcinoma tissues. 185
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. 182
Genistein affects adipose tissue deposition in a dose-dependent and gender-specific manner. 182
Trop-2 protein overexpression is an independent marker for predicting disease recurrence in endometrioid endometrial carcinoma 181
RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients 178
Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence 177
MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis 172
Overexpression of mammaglobin B in epithelial ovarian carcinomas. 171
Immunotherapy for the prevention of high-risk oral disorders malignant transformation: the IMPEDE trial 169
Trefoil factor 3: a novel serum marker identified by gene expression profiling in highgrade endometrial carcinomas 168
Mammaglobin B expression in human endometrial cancer 165
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma 160
Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy 159
Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome 152
Claudin-7 expression in human epithelial ovarian cancer 146
Claudin 7 downregulation is predictive of distant metastasis in high-grade serous carcinoma patients 142
Improved Risk Prediction in Human Papillomavirus-Associated Endocervical Adenocarcinoma Through Assessment of Binary Silva Pattern-based Classification: An International Multicenter Retrospective Observational Study Led by the International Society of Gynecological Pathologists (ISGyP) 139
Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer 136
Gene expression profiling of olfactory neuroblastoma helps identify prognostic pathways and define potentially therapeutic targets 136
LncRNAs as novel indicators of patients' prognosis in stage i epithelial ovarian cancer: A retrospective and multicentric study 132
Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients 128
Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients 115
Uso di miRNA come biomarcatori per la diagnosi e prognosi del carcinoma orale a cellule squamose 114
Integrated mutational landscape analysis of uterine leiomyosarcomas 112
FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients 111
L1CAM expression as a predictor of platinum response in high-risk endometrial carcinoma 102
Infiltration by CXCL10 Secreting Macrophages Is Associated With Antitumor Immunity and Response to Therapy in Ovarian Cancer Subtypes 96
Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 91
Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy 83
Correction for Li et al., Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors 83
Revisiting the concept of neoadjuvant and induction therapy in head and neck cancer with the advent of immunotherapy 77
Identification of optimal reference RNAs to normalize miRNA expression data by qRT-PCR in formalin-fixed, paraffin-embedded lymph node tissue 70
The Oxford Classic can identify HGSOC patients who may benefit from EMT-targeting therapies 70
Circulating Serum Micro-RNA as Non-Invasive Diagnostic Biomarkers of Endometriosis 66
Development of a diagnostic model based on serum microRNAs for the diagnosis of endometriosis 45
Oxford Classic-Defined EMT Risk Stratification of High-Grade Serous Ovarian Cancer for Guiding Treatment Decisions 19
Serum miRNA-based diagnostic models for endometriosis: from discovery to validation 11
Totale 7.896
Categoria #
all - tutte 32.361
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.361


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021259 0 0 0 0 0 0 0 0 0 141 68 50
2021/2022442 64 91 7 3 5 27 28 21 15 59 38 84
2022/2023493 76 32 25 32 47 102 8 52 69 6 24 20
2023/2024619 36 19 64 54 33 165 34 37 80 37 9 51
2024/20251.157 22 20 19 201 79 124 74 45 119 74 215 165
2025/20262.325 239 212 162 354 318 210 410 88 151 181 0 0
Totale 7.896